Astrazeneca plc ADR (AZN) concluded trading on Wednesday at a closing price of $68.20, with 5.95 million shares of worth about $405.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.85% during that period and on January 22, 2025 the price saw a gain of about 0.35%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of 4.33% in past 5 days and over the past one month there was a price change of 5.51%. Year-to-date (YTD), AZN shares are showing a performance of 4.09% which increased to 2.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.47 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 6.09 million. The stock is currently trading 2.73% above its 20-day simple moving average (SMA20), while that difference is up 3.17% for SMA50 and it goes to -8.96% lower than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 15.80% of that.
The stock has a current market capitalization of $211.50B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 32.77, while it has posted earnings per share of $2.08 in the same period. Its PEG reads 2.41 and has Quick Ratio of 0.71 while making debt-to-equity ratio of 0.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.42% while standing at 1.32% over the month.
Analysts are in expectations that Astrazeneca plc ADR (AZN) stock would likely to be making an EPS of 1.09 in the current quarter, while forecast for next quarter EPS is 1.07 and it is 4.72 for next year. For the current quarter EPS, analysts have given the company a lowest target 1.02 which is 1.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.73 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.24% while it is estimated to increase by 12.91% in next year. EPS is likely to shrink at an annualized rate of 13.62% for next 5-years, compared to annual growth of 17.72% made by the stock over the past 5-years.
On September 13, 2024, Deutsche Bank Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $97. Stock get a Hold rating from Deutsche Bank on April 16, 2024.
